Universe Pharmaceuticals INC
UPC
$4.20
$0.4010.53%
NASDAQ
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.23% | -30.23% | -13.17% | -13.17% | -23.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.23% | -30.23% | -13.17% | -13.17% | -23.70% |
| Cost of Revenue | -22.89% | -22.89% | 23.68% | 23.68% | 18.12% |
| Gross Profit | -45.02% | -45.02% | -48.53% | -48.53% | -55.45% |
| SG&A Expenses | 37.48% | 37.48% | -51.28% | -51.28% | -66.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -123.36% | -123.36% | -5.56% | -5.56% | -8.61% |
| Total Operating Expenses | -20.16% | -20.16% | -32.83% | -32.83% | -14.80% |
| Operating Income | -1,266.35% | -1,266.35% | 63.75% | 63.75% | -94.48% |
| Income Before Tax | -4,901.70% | -4,901.70% | 63.62% | 63.62% | -92.18% |
| Income Tax Expenses | -31.73% | -31.73% | 262.17% | 262.17% | -38.26% |
| Earnings from Continuing Operations | -1,731.34% | -1,731.34% | 47.96% | 47.96% | -141.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,731.34% | -1,731.34% | 47.96% | 47.96% | -141.31% |
| EBIT | -1,266.35% | -1,266.35% | 63.75% | 63.75% | -94.48% |
| EBITDA | -466.39% | -466.39% | 65.40% | 65.40% | -86.40% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |